A Phase 3 interventional study of ISL and DOR in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 98 sites in 18 countries. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART).
Part 1 of this study (Day 1 to Day 7) is the double-blind period in which participants receive either ISL, DOR, DOR/ISL, or placebo. Part 2 of this study (Day 8 to Week 97) is the open-label period in which all participants receive DOR/ISL + optimized background therapy (OBT).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL fixed dose combination (FDC) QD + OBT from Day 8 to Week 97.
Drug: ISL · Drug: DOR/ISL
HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
Drug: DOR · Drug: DOR/ISL
HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
Drug: DOR/ISL
HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
Drug: DOR/ISL · Drug: Placebo to ISL · Drug: Placebo to DOR
ISL 0.75 mg capsule taken by mouth.
Also known as: Islatravir, MK-8591
DOR 100 mg tablet taken by mouth.
Also known as: Doravirine, MK-1439
Drug pages: Doravirine · Islatravir
100 mg DOR/0.75 mg ISL FDC taken by mouth.
Also known as: Doravirine/Islatravir, MK-8591A
Placebo capsule matched to ISL taken by mouth.
Placebo tablet matched to DOR taken by mouth.
Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment
Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL FDC or placebo were analyzed in this outcome measure.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants With ≥1 AEs Through Week 49
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 49 weeks
Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 25
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 25 weeks
Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 25
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 25 weeks
Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 49
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 49 weeks
Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 97
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 97 weeks
Percentage of Participants Discontinuing From Study Therapy Due to AE(s) Through Week 97
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 97 weeks
Percentage of Participants Receiving DOR or ISL (Given With Antiretroviral Therapy [ART]) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment
Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time PCR assay which has a LLOD of 40 copies/mL Only participants treated with either DOR or ISL or placebo (given with ART) were analyzed in this outcome measure. Participants treated with DOR/ISL FDC were not analyzed in this outcome measure.
Time frame: Day 1 (baseline) and Day 8
Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART), DOR, or ISL Compared to Placebo Treatment
The change from baseline Day to Day 8 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants Receiving DOR/ISL (Given With ART), DOR, or ISL With ≥1.0 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment
Participants with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a LLOD of 40 copies/mL
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment
Participants with a ≥0.5 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.
Time frame: Day 1 (baseline) and Day 8
Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART) Compared to DOR or ISL Treatment
The change from baseline Day 1 to Day 8in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the t-distribution. The group treated with placebo were not analyzed in this outcome measure.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥1.0 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment
Participants receiving DOR/ISL with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 25
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 49
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 97
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 25
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 49
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 97
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 25
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 49
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 97
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 25
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 49
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 97
Mean Change From Baseline Day 1 to Week 25 in HIV-1 RNA From the Pooled Treatment Group
The change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 25
Mean Change From Baseline Day 1 to Week 49 in HIV-1 RNA From the Pooled Treatment Group
The change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 49
Mean Change From Baseline Day 1 to Week 97 in HIV-1 RNA From the Pooled Treatment Group
The change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 97
Mean Change From Baseline Day 8 to Week 25 in HIV-1 RNA From the Pooled Treatment Group
The change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 25
Mean Change From Baseline Day 8 to Week 49 in HIV-1 RNA From the Pooled Treatment Group
The change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 49
Mean Change From Baseline Day 8 to Week 97 in HIV-1 RNA From the Pooled Treatment Group
The change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 97
Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <200 Copies mL
The percentage of participants with HIV-1 RNA \<200 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <50 Copies mL
The percentage of participants with HIV-1 RNA \<50 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <40 Copies mL
The percentage of participants with HIV-1 RNA \<40 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.
Time frame: Day 1 (baseline) and Day 8
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 25
The percentage of participants with HIV-1 RNA \<200 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 25
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 49
The percentage of participants with HIV-1 RNA \<200 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 49
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 97
The percentage of participants with HIV-1 RNA \<200 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 97
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 25
The percentage of participants with HIV-1 RNA \<50 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 25
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 49
The percentage of participants with HIV-1 RNA \<50 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 49
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 97
The percentage of participants with HIV-1 RNA \<50 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 97
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 25
The percentage of participants with HIV-1 RNA \<40 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 25
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 49
The percentage of participants with HIV-1 RNA \<40 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 49
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 97
The percentage of participants with HIV-1 RNA \<40 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 97
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 25
The prevalence of viral drug resistance to DOR was based on the percentage of participants with treatment-emergent (TE) resistance-associated substitutions (RASs), which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 25
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 49
The prevalence of viral drug resistance to DOR was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 49
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 25
The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 25
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 49
The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 49
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to Optimized Background Therapy (OBT) Components at Week 25
The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 25
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to OBT Components at Week 49
The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
Time frame: Week 49
Number of Participants From the Pooled Treatment Group With Viral Resistance-associated Substitutions (RASs) at Week 25
The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 25 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 25
Number of Participants From the Pooled Treatment Group With Viral RASs at Week 49
The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 49 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 49
Number of Participants From the Pooled Treatment Group With Viral RASs at Week 97
The number of participants from the pooled treatment group with treatment emergent RAS at week 97 are presented, showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 97
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 25
The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 25 is presented. .Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 25
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 49
The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 49 is presented. .Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 49
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 97
The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 97 is presented. .Analysis of the pooled treatment group was planned per protocol,
Time frame: Week 97
Change From Baseline Day 1 to Week 25 in Cluster of Differentiation 4+ (CD4+) T-cell Counts From the Pooled Treatment Group
The change from baseline Day 1 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 25
Change From Baseline Day 1 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group
The change from baseline Day 1 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 49
Change From Baseline Day 1 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group
The change from baseline Day 1 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 1 (baseline) and Week 97
Change From Baseline Day 8 to Week 25 in CD4+ T-cell Counts From the Pooled Treatment Group
The change from baseline Day 8 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 25
Change From Baseline Day 8 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group
The change from baseline Day 8 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 49
Change From Baseline Day 8 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group
The change from baseline Day 8 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
Time frame: Day 8 (baseline) and Week 97
Heavily Treatment-Experienced (HTE) adult participants with Human Immunodeficiency Virus Type 1 (HIV-1) infection and currently on failing antiretroviral therapy (ART) were enrolled in this study.
| Milestone | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Started | 7 | 14 | 7 | 7 |
| Completed | 6 | 9 | 4 | 5 |
| Not completed | 1 | 5 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 3 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 0 |
Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL FDC or placebo were analyzed in this outcome measure.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment | — | — | 85.7 (42.1 to 99.6) | 0.0 (0.0 to 41.0) |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants With ≥1 AEs Through Week 49 | 71.4 | 85.7 | 85.7 | 85.7 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 25 | 0.0 | 7.1 | 14.3 | 0.0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 25 | 42.9 | 85.7 | 85.7 | 85.7 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 49 | 0.0 | 14.3 | 14.3 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 97 | 85.7 | 100.0 | 85.7 | 100.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Discontinuing From Study Therapy Due to AE(s) Through Week 97 | 0.0 | 21.4 | 28.6 | 14.3 |
Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time PCR assay which has a LLOD of 40 copies/mL Only participants treated with either DOR or ISL or placebo (given with ART) were analyzed in this outcome measure. Participants treated with DOR/ISL FDC were not analyzed in this outcome measure.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Receiving DOR or ISL (Given With Antiretroviral Therapy [ART]) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment | 28.6 (3.7 to 71.0) | 78.6 (49.2 to 95.3) | — | 0.0 (0.0 to 41.0) |
The change from baseline Day to Day 8 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution.
| Log10 Copies/mL | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART), DOR, or ISL Compared to Placebo Treatment | -0.44 (-0.96 to 0.07) | -0.96 (-1.38 to -0.54) | -1.23 (-1.72 to -0.75) | 0.03 (-0.15 to 0.21) |
Participants with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a LLOD of 40 copies/mL
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Receiving DOR/ISL (Given With ART), DOR, or ISL With ≥1.0 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment | 14.3 (0.4 to 57.9) | 50.0 (23.0 to 77.0) | 85.7 (42.1 to 99.6) | 0.0 (0.0 to 41.0) |
Participants with a ≥0.5 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment | 28.6 (3.7 to 71.0) | 78.6 (49.2 to 95.3) | 85.7 (42.1 to 99.6) | — |
The change from baseline Day 1 to Day 8in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the t-distribution. The group treated with placebo were not analyzed in this outcome measure.
| Log10 Copies/mL | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART) Compared to DOR or ISL Treatment | -0.44 (-0.96 to 0.07) | -0.96 (-1.38 to -0.54) | -1.23 (-1.72 to -0.75) | — |
Participants receiving DOR/ISL with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥1.0 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment | 14.3 (0.4 to 57.9) | 50.0 (23.0 to 77.0) | 85.7 (42.1 to 99.6) | — |
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA | 85.3 (68.9 to 95.0) |
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA | 80.6 (62.5 to 92.5) |
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA | 84.6 (65.1 to 95.6) |
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA | 64.7 (46.5 to 80.3) |
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA | 67.7 (48.6 to 83.3) |
The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA | 69.2 (48.2 to 85.7) |
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA | 67.6 (49.5 to 82.6) |
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA | 71.0 (52.0 to 85.8) |
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA | 73.1 (52.2 to 88.4) |
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA | 58.8 (40.7 to 75.4) |
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA | 61.3 (42.2 to 78.2) |
The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA | 61.5 (40.6 to 79.8) |
The change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| Log10 Copies/mL | Pooled Treatment |
|---|---|
| Mean Change From Baseline Day 1 to Week 25 in HIV-1 RNA From the Pooled Treatment Group | -1.89 (-2.33 to -1.45) |
The change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| Log10 Copies/mL | Pooled Treatment |
|---|---|
| Mean Change From Baseline Day 1 to Week 49 in HIV-1 RNA From the Pooled Treatment Group | -2.00 (-2.47 to -1.53) |
The change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| Log10 Copies/mL | Pooled Treatment |
|---|---|
| Mean Change From Baseline Day 1 to Week 97 in HIV-1 RNA From the Pooled Treatment Group | -2.01 (-2.51 to -1.52) |
The change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| Log10 Copies/mL | Pooled Treatment |
|---|---|
| Mean Change From Baseline Day 8 to Week 25 in HIV-1 RNA From the Pooled Treatment Group | -1.16 (-1.56 to -0.77) |
The change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| Log10 Copies/mL | Pooled Treatment |
|---|---|
| Mean Change From Baseline Day 8 to Week 49 in HIV-1 RNA From the Pooled Treatment Group | -1.32 (-1.72 to -0.91) |
The change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| Log10 Copies/mL | Pooled Treatment |
|---|---|
| Mean Change From Baseline Day 8 to Week 97 in HIV-1 RNA From the Pooled Treatment Group | -1.36 (-1.83 to -0.89) |
The percentage of participants with HIV-1 RNA \<200 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Day 1 | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 41.0) |
| Day 8 | 0.0 (0.0 to 41.0) | 14.3 (1.8 to 42.8) | 14.3 (0.4 to 57.9) | 0.0 (0.0 to 41.0) |
The percentage of participants with HIV-1 RNA \<50 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Day 1 | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 41.0) |
| Day 8 | 0.0 (0.0 to 41.0) | 14.3 (1.8 to 42.8) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 41.0) |
The percentage of participants with HIV-1 RNA \<40 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.
| Percentage of participants | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART |
|---|---|---|---|---|
| Day 1 | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 41.0) |
| Day 8 | 0.0 (0.0 to 41.0) | 14.3 (1.8 to 42.8) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 41.0) |
The percentage of participants with HIV-1 RNA \<200 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 25 | 64.7 (46.5 to 80.3) |
The percentage of participants with HIV-1 RNA \<200 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 49 | 77.4 (58.9 to 90.4) |
The percentage of participants with HIV-1 RNA \<200 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 97 | 80.8 (60.6 to 93.4) |
The percentage of participants with HIV-1 RNA \<50 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 25 | 58.8 (40.7 to 75.4) |
The percentage of participants with HIV-1 RNA \<50 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 49 | 71.0 (52.0 to 85.8) |
The percentage of participants with HIV-1 RNA \<50 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 97 | 69.2 (48.2 to 85.7) |
The percentage of participants with HIV-1 RNA \<40 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 25 | 58.8 (40.7 to 75.4) |
The percentage of participants with HIV-1 RNA \<40 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 49 | 71.0 (52.0 to 85.8) |
The percentage of participants with HIV-1 RNA \<40 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 97 | 69.2 (48.2 to 85.7) |
The prevalence of viral drug resistance to DOR was based on the percentage of participants with treatment-emergent (TE) resistance-associated substitutions (RASs), which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 25 | 33.3 |
The prevalence of viral drug resistance to DOR was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 49 | 28.6 |
The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 25 | 8.3 |
The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 49 | 14.3 |
The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to Optimized Background Therapy (OBT) Components at Week 25 | 25.0 |
The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.
| Percentage of participants | Pooled Treatment |
|---|---|
| Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to OBT Components at Week 49 | 28.6 |
The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 25 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,
| Participants | Pooled Treatment |
|---|---|
| RAS A98G | 2 |
| RAS D67N | 1 |
| RAS H221Y | 1 |
| RAS K103S | 1 |
| RAS K219E | 1 |
| RAS L234I | 1 |
| RAS M184V | 1 |
| RAS M41L | 1 |
| RAS N348I | 1 |
| RAS V106A | 3 |
| RAS V106I | 2 |
| RAS V106M | 1 |
| RAS V179I | 2 |
| RAS Y318F | 1 |
| RAS F53L | 1 |
| RAS L90M | 1 |
| RAS M36I | 1 |
The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 49 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,
| Participants | Pooled Treatment |
|---|---|
| RAS A98G | 1 |
| RAS D67N | 1 |
| RAS K103S | 1 |
| RAS K219E | 1 |
| RAS M184V | 1 |
| RAS M41L | 1 |
| RAS N348I | 1 |
| RAS V106A | 2 |
| RAS V106I | 1 |
| RAS V106M | 1 |
| RAS V179I | 2 |
| RAS F53L | 1 |
| RAS L90M | 1 |
| RAS M36I | 1 |
The number of participants from the pooled treatment group with treatment emergent RAS at week 97 are presented, showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,
| Participants | Pooled Treatment |
|---|---|
| RAS D67N | 1 |
| RAS M41L | 1 |
| RAS N348I | 1 |
| RAS T215F | 1 |
| RAS V106A | 2 |
| RAS V106I | 1 |
| RAS V106M | 1 |
| RAS V179I | 1 |
| RAS F53L | 1 |
| RAS L90M | 1 |
| RAS M36I | 1 |
The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 25 is presented. .Analysis of the pooled treatment group was planned per protocol,
| Participants | Pooled Treatment |
|---|---|
| Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 25 | 12 |
The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 49 is presented. .Analysis of the pooled treatment group was planned per protocol,
| Participants | Pooled Treatment |
|---|---|
| Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 49 | 7 |
The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 97 is presented. .Analysis of the pooled treatment group was planned per protocol,
| Participants | Pooled Treatment |
|---|---|
| Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 97 | 5 |
The change from baseline Day 1 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| cells/mm^3 | Pooled Treatment |
|---|---|
| Change From Baseline Day 1 to Week 25 in Cluster of Differentiation 4+ (CD4+) T-cell Counts From the Pooled Treatment Group | 50.3 (27.8 to 72.9) |
The change from baseline Day 1 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| cells/mm^3 | Pooled Treatment |
|---|---|
| Change From Baseline Day 1 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group | 86.9 (51.2 to 122.5) |
The change from baseline Day 1 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| cells/mm^3 | Pooled Treatment |
|---|---|
| Change From Baseline Day 1 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group | 114.6 (54.7 to 174.6) |
The change from baseline Day 8 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| cells/mm^3 | Pooled Treatment |
|---|---|
| Change From Baseline Day 8 to Week 25 in CD4+ T-cell Counts From the Pooled Treatment Group | 38.0 (9.6 to 66.4) |
The change from baseline Day 8 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| cells/mm^3 | Pooled Treatment |
|---|---|
| Change From Baseline Day 8 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group | 75.1 (36.9 to 113.4) |
The change from baseline Day 8 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,
| cells/mm^3 | Pooled Treatment |
|---|---|
| Change From Baseline Day 8 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group | 108.0 (47.9 to 168.2) |
Collected over All-Cause Mortality (ACM): from randomization up to Week 49; Adverse Events (AE): from treatment ( Day 1) Up to Week 97. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ISL+ART | 0/7 (0%) | 2/7 (28.6%) | 6/7 (85.7%) |
| DOR+ART | 0/14 (0%) | 2/14 (14.3%) | 14/14 (100%) |
| DOR/ISL+ART | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Placebo+ART | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Event | ISL+ART | DOR+ART | DOR/ISL+ART | Placebo+ART |
|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/7 | 0/14 | 0/7 | 1/7 |
| Colitis ulcerativeGastrointestinal disorders | 0/7 | 0/14 | 0/7 | 1/7 |
| COVID-19 pneumoniaInfections and infestations | 1/7 | 0/14 | 0/7 | 0/7 |
| SARS-CoV-2 sepsisInfections and infestations | 1/7 | 0/14 | 0/7 | 0/7 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/7 | 0/14 | 0/7 | 0/7 |
| Reactive gastropathyInjury, poisoning and procedural complications | 0/7 | 0/14 | 0/7 | 1/7 |
| COVID-19Infections and infestations | 0/7 | 1/14 | 0/7 | 0/7 |
| Postoperative wound infectionInfections and infestations | 0/7 | 1/14 | 0/7 | 0/7 |
| Castleman's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 1/14 | 0/7 | 0/7 |
| Event | ISL+ART | DOR+ART | DOR/ISL+ART | Placebo+ART |
|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 0/7 | 5/14 | 0/7 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 4/14 | 2/7 | 1/7 |
| Chest painGeneral disorders | 1/7 | 1/14 | 1/7 | 2/7 |
| COVID-19Infections and infestations | 1/7 | 4/14 | 0/7 | 2/7 |
| Blood creatine phosphokinase increasedInvestigations | 0/7 | 1/14 | 2/7 | 1/7 |
| Creatinine renal clearance decreasedInvestigations | 2/7 | 3/14 | 0/7 | 1/7 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/7 | 0/14 | 0/7 | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 1/14 | 1/7 | 0/7 |
| CataractEye disorders | 0/7 | 0/14 | 0/7 | 1/7 |
| Eye allergyEye disorders | 0/7 | 0/14 | 0/7 | 1/7 |
| Age, Continuous(Years) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| Mean | 46.6 ± 12.7 | 48.6 ± 11.8 | 54.0 ± 10.0 | 44.6 ± 9.1 | 48.5 ± 11.1 |
| Sex: Female, Male(Participants) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 1 | 1 | 8 |
| Male | 5 | 10 | 6 | 6 | 27 |
| Ethnicity (NIH/OMB)(Participants) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 0 | 4 |
| Not Hispanic or Latino | 7 | 12 | 5 | 7 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 0 | 1 | 11 |
| White | 2 | 7 | 6 | 5 | 20 |
| More than one race | 0 | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Plasma HIV-1 RNA(Log10 copies/mL) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| Mean | 4.1 ± 0.8 | 4.3 ± 0.9 | 4.5 ± 0.8 | 4.2 ± 0.7 | 4.3 ± 0.8 |
| Custer of differentiation 4+ (CD4+) T-cell Count(cells/mm^3) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| Mean | 166.3 ± 121.7 | 132.4 ± 136.6 | 178.6 ± 135.5 | 132.6 ± 100.7 | 148.5 ± 123.3 |
| Genotypic resistance(Participants) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| Nucleos(t)ide reverse transcriptase inhibitor (NRTI) substitutions | 7 | 14 | 7 | 7 | 35 |
| Non-nucleoside reverse transcriptase inhibitor (NNRTI) substitutions | 7 | 14 | 7 | 7 | 35 |
| Protease inhibitor (PI) substitutions | 7 | 14 | 7 | 7 | 35 |
| Integrase strand transfer inhibitor (InSTI )substitutions | 5 | 9 | 5 | 6 | 25 |
| Phenotypic resistance(Participants) | ISL + ART | DOR + ART | DOR/ISL + ART | Placebo + ART | Total |
|---|---|---|---|---|---|
| NRTI | 7 | 14 | 7 | 7 | 35 |
| NNRTI | 6 | 13 | 7 | 7 | 33 |
| PI | 7 | 12 | 7 | 6 | 32 |
| InSTI | 5 | 9 | 5 | 7 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2020 to primary completion in Nov 2022, 32 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Islatravir · Doravirine